

Geneva, 6<sup>th</sup> August 2021 FSCA 5286

# Please distribute to the Laboratory Manager – URGENT FIELD SAFETY NOTICE– VIDAS® EBV VCA IgM (Ref. 30237) – Calibration issue with a potential risk of delayed results and false negative results

Response required

Dear bioMérieux Customer,

Our records indicate that your laboratory received the lot indicated in table 1 below.

#### **Table 1: List of impacted lots:**

Product	Reference	Lot #	Expiry date
VIDAS® EBV VCA IgM	30237	1008591990	27-Jan-2022

#### **Description of the issue:**

Based on complaints reported from the field for invalid calibration with VIDAS® EBV VCA IGM (Ref. 30237) lot. #1008591990 due to S1 value out-of-range too low, bioMérieux has initiated an investigation to confirm product issue and identify the root cause.

To date, the investigation confirmed the calibration issue on the impacted lot.#1008591990.

Also, the investigation showed that all internal samples used for the control of this lot were within their specifications. There were no false negative results.

In case of invalid calibration, an error message appears and it will not be possible to perform further testing. In case of valid calibration, the kit can be used as usual and there is no need to perform any retrospective analysis of previous results obtained with the impacted lot.

Other lots of the product reference VIDAS® EBV VCA IGM (Ref. 30237) are conform to the specifications and will be monitored closely until the root cause is identified.

#### **Impact to customer:**

In case of invalid calibration, there is a risk of delayed results as further analysis cannot be done on patient samples. In case of valid calibration, the results obtained will be correct. Also, as the root-cause has not been identified yet, bioMérieux still doesn't know if the issue is related to a decrease of the S1 value or related to the strip. Therefore, there is a potential risk of false negative result between the last valid calibration and the first invalid calibration, 28 days later (as per recommendation for recalibration of the kit). In this case, between both calibrations, there is a potential risk of false negative result if you have not tested a control in parallel of the sera.



#### **Required actions:**

We request you to take the following actions at this time:

- Please distribute this information to all appropriate personnel in your laboratory, retain a copy in your files, and forward this information to all parties that may use this product, including others to whom you may have transferred our product.
- Stop using and destroy any kits of lot. #1008591990 in Table 1 remaining in your inventory.
- Discuss any concerns you may have regarding previously reported patient results obtained since the last valid calibration with your Laboratory Medical Director to determine the appropriate course of action. Results should be reviewed and interpreted in the context of the overall clinical picture.
- Please complete the Acknowledgement of Receipt Form and return it to your local bioMérieux representative (Email: <a href="mailto:ch\_support@biomerieux.com">ch\_support@biomerieux.com</a>; Fax 022 906 57 42)
   On receipt, we will make a credit note corresponding to the number of kit(s) you have destroyed.

bioMérieux is committed to providing our customers with the highest quality product possible.

We sincerely apologize for any inconvenience that this may have caused you. If you require additional assistance or have any questions, please contact the Scientific Customer Service of bioMérieux at 022 906 57 96.

Sincerly

bioMérieux (Suisse) SA

Sassina Welf

Sabrina Wulf

**Product Manager Immunoassays** 

Attachment A: Acknowledgement Form



## Attachment A: Acknowledgement Form URGENT FIELD SAFETY NOTICE

## FSCA 5286 - VIDAS® EBV VCA IGM Ref. 30237 - Calibration issue Response required

In compliance with legal traceability requirements we thank you for completing this form even if you no longer have this reagent.

### Please return the form to your customer service per email (<a href="mailto:ch\_support@biomerieux.com">ch\_support@biomerieux.com</a>) or fax (022 906 57 42)

	me of the laboratory:				
Co	ntact person:				
Cit	y and postal Code :				
Cu	stomer No. :				
Pro	duct Information:				
	n your signature you co A IGM Ref. 30237 – Cal			bioMérieux letter regard	ding the "VIDAS® EB
	ı confirm that you will im AS <sup>®</sup> EBV VCA IGM Re			top using and destroy the ent Field Safety Notice.	e affected lot of
Hav	ve you encountered imp	pact on patients	s' results, or repo	orts of illness or injury re	elated to the identifie
	□ No	□ Yes			
issu	-		r for contacting y	ou:	
issu	-		r for contacting y	ou:Quantity Received	Quantity Destroyed

DATE .....

SIGNATURE .....